fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Glyburide

All products: general benefit

Sandoz Glyburide · DIN 02248008 · 2.5 mg · tablet

General benefit; Health Canada lists this DIN as Cancelled post market since 2017-08-01 — choose a marketed DIN from the same-category list.Discontinued August 1, 2017 · checked November 17, 2026
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2017-08-01 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2017-08-01 — choose a marketed DIN from the same-category list.
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
1 brand, same coverage
Sandoz Glyburide · DIN 02248008 Manufacturer: Sandoz Canada Inc.; listing date 2004-07-20 Health Canada: Cancelled post market since 2017-08-01 · brand SANDOZ GLYBURIDE · ATC A10BB01 GLIBENCLAMIDE · form Tablet · route Oral · ingredients GLYBURIDE 2.5 MG · company Sandoz canada incorporated · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Sandoz Glyburide: Formulary list price $0.03 per unit (the source does not state the unit; exact figure $0.0321). What the ministry pays, not the patient.

Ministry pays: $0.0321 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02248008)

Source record
DIN 02248008: Sandoz Glyburide Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y Item: 682002009; group id 747; item number 1829; lccId None; manufacturer id SDZ Source form: Tab; strength: 2.5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag Source prices (unrounded): $0.0321; ministry $0.0321 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02248008 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=72324
Interchangeable products
Apo-Glyburide · DIN 01913654 · $0.0321 Diabeta · DIN 02224550 · not recorded Teva-Glyburide · DIN 01913670 · $0.0321
Shortage status: not checked (no credentials)
Health Canada lists this DIN as Cancelled post market since August 1, 2017 — choose a marketed DIN from the same-category list.

Other products in the same Health Canada class (A10B, A10BB): coverage varies; not interchangeable

  • Gliclazide (Diamicron MR): general benefit, not a benefit
  • Glimepiride (Amaryl): not a benefit
  • Canagliflozin (Invokana): general benefit
  • Dapagliflozin (Forxiga): general benefit
  • Dapagliflozin + metformin (Xigduo): general benefit
  • Empagliflozin (Jardiance): general benefit

12 more in the class list below

Other drugs in the same formulary class (68:20:02 Oral Anti-Diabetic Agents) and how they are covered

Matched class: 68:20:02 Oral Anti-Diabetic Agents

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: CANAGLIFLOZIN, DAPAGLIFLOZIN, DAPAGLIFLOZIN & METFORMIN, EMPAGLIFLOZIN, EMPAGLIFLOZIN & METFORMIN, LINAGLIPTIN, LINAGLIPTIN & METFORMIN, SAXAGLIPTIN, SAXAGLIPTIN & METFORMIN, SITAGLIPTIN, SITAGLIPTIN & METFORMIN Some products covered without a code (check the product listing): GLICLAZIDE, METFORMIN HCL 68:20:02 Oral Anti-Diabetic Agents

GLICLAZIDE

· 19 products · General benefit (18), Listed, not a benefit (1) · strengths: 60mg, 30mg, 80mg · ER Tab, SR Tab, Tab

GLIMEPIRIDE

· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 1mg, 2mg, 4mg · Tab

CANAGLIFLOZIN

· 8 products · General benefit · strengths: 100mg, 300mg · Tab

DAPAGLIFLOZIN

· 22 products · General benefit · strengths: 5mg, 10mg · Tab

DAPAGLIFLOZIN & METFORMIN

· 6 products · General benefit · strengths: 5mg & 1000mg, 5mg & 850mg · Tab

EMPAGLIFLOZIN

· 2 products · General benefit · strengths: 10mg, 25mg · Tab

EMPAGLIFLOZIN & METFORMIN

· 6 products · General benefit · strengths: 5mg & 1000mg, 5mg & 500mg, 5mg & 850mg, 12.5mg & 1000mg, 12.5mg & 500mg, 12.5mg & 850mg · Tab

LINAGLIPTIN

· 1 products · General benefit · strengths: 5mg · Tab

LINAGLIPTIN & METFORMIN

· 3 products · General benefit · strengths: 2.5mg & 1000mg, 2.5mg & 500mg, 2.5mg & 850mg · Tab

METFORMIN HCL

· 53 products · Off-Formulary Interchangeable, not an ODB benefit (33), General benefit (19), Off-Formulary Interchangeable, not an ODB benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (1) · strengths: 500mg, 1000mg, 850mg · ER Tab, Tab

SAXAGLIPTIN

· 6 products · General benefit · strengths: 2.5mg, 5mg · Tab

SAXAGLIPTIN & METFORMIN

· 3 products · General benefit · strengths: 2.5mg & 1000mg, 2.5mg & 500mg, 2.5mg & 850mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 68:20:02 and 6 more
Full class listing Related classes: 68:20:06 Incretin Mimetics, 68:20:10 Insulins (Rapid Acting), 68:20:12 Insulins (Intermediate Acting), 68:20:14 Insulins (Long Acting), 68:20:16 Insulins (Pre-Mixed) Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE APO-GLYBURIDE (glyburide) is indicated as an adjunct to proper dietary management, exercise and weight reduction to lower blood glucose in adult patients with type 2 diabetes whose hyperglycemia cannot be controlled by diet and exercise alone or when insulin therapy is not required. Pediatrics (<18 years of age) Safety and effectiveness of glyburide has not been established. Use in patients under 18 years of age is not recommended (see WARNING AND PRECAUTIONS, Special Populations). Geriatrics Elderly with type 2 diabetes when treated with glyburide are more prone to hypoglycemia (see WARNINGS AND PRECAUTIONS, Special Populations). https://pdf.hres.ca/dpd_pm/00038563.PDF PM date: March 20, 2017 Source product: APO GLYBURIDE TAB 2.5MG; DIN 01913654; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.